Urokinase

This product directly acts on the endogenous fibrinolytic system to catalyze the cleavage of plasminogen into plasmin, which can not only degrade fibrin clots, but also degrade fibrinogen, coagulation factor V and coagulation factor VIII in the blood circulation, thereby exerting a thrombolytic effect. This product has a fast onset and good effect on newly formed thrombi. This product can also increase the activity of vascular ADP enzymes, inhibit ADP-induced platelet aggregation, and prevent thrombosis. After intravenous infusion of this product, the activity of plasmin in the patient's body is significantly increased; a few hours after drug withdrawal, plasmin activity returns to its original level, but the decrease in plasma fibrin or fibrinogen levels and the increase in their degradation products can last for 12-24 hours. This product shows a significant correlation between the thrombolytic effect and the drug dose and the time window of administration. The product has very low toxicity, and the median lethal dose of intravenous injection in mice is greater than 1 million international units/kg body weight. There is also no obvious antigenicity, teratogenicity, carcinogenicity and mutagenicity. Allergic reactions are rarely reported in clinical use; however, given that this product increases plasmin activity and reduces unbound plasminogen and fibrin-bound plasminogen in the blood circulation, there may be a risk of serious bleeding.

Urokinase

This product is mainly used for thrombolytic therapy of thromboembolic diseases. Including acute extensive pulmonary embolism, coronary artery embolism and myocardial infarction within 6-12 hours of chest pain, acute cerebral vascular embolism with symptoms shorter than 3-6 hours, retinal artery embolism and other patients with severe iliac-femoral vein thrombosis with peripheral arterial embolism symptoms. It is also used to prevent thrombosis after artificial heart valve surgery, maintain patency of vascular cannulation and chest and pericardial drainage tubes, etc. The efficacy of thrombolysis requires subsequent heparin anticoagulation to maintain.

1. When using a large dose, a small number of patients may have bleeding. Mild bleeding such as hematuria, bloody sputum or a small amount of hemoptysis or hematemesis under the skin, mucous membrane, naked eye and microscope can relieve symptoms by taking appropriate measures. If severe bleeding occurs, such as massive hemoptysis or massive gastrointestinal bleeding, retroperitoneal bleeding, and intracranial, spinal cord, mediastinal or pericardial bleeding, the drug should be discontinued. Blood loss can be effectively controlled by transfusing whole blood (preferably fresh blood, not plasma substitutes). In an emergency, aminocaproic acid and aminomethylbenzoic acid can be considered to counteract the effect of urokinase. 2. A small number of patients may have allergic reactions: generally mild, such as bronchospasm, rash, etc. Anaphylactic shock can occasionally be seen. 3. Fever: About 2-3% of patients can have varying degrees of fever. Acetaminophen can be used as an antipyretic. Aspirin or other antipyretic drugs with antiplatelet effects cannot be used. 4. Others: Nausea, vomiting, loss of appetite, fatigue, and ALT elevation may occur. It may cause bleeding, and in a few cases, allergic reactions. If symptoms such as headache, nausea, vomiting, or loss of appetite occur, the drug should be discontinued immediately.

The following conditions are contraindicated: 1. Patients with recent (within 14 days) active bleeding (gastric and duodenal ulcers, hemoptysis, hemorrhoids, bleeding, etc.), surgery, biopsy, cardiopulmonary resuscitation (external cardiac massage, intracardiac injection, endotracheal intubation), vascular puncture at the site of compression that cannot be performed, and history of trauma; 2. Patients with unsatisfactory control of hypertension (blood pressure 21.3/14.7kPa) or aortic dissection aneurysm that cannot be ruled out; 3. Patients with a history of hemorrhagic stroke (including transient ischemic attack); 4. Shock that does not respond to volume expansion and vasopressor drugs; 5. Pregnancy, bacterial endocarditis, mitral valve disease and atrial fibrillation, and highly suspected left heart thrombosis; 6. Diabetes with retinopathy; 7. Hemorrhagic disease or bleeding tendency, severe liver and kidney dysfunction and progressive disease; 8. Patients with impaired consciousness. 9. Patients with severe liver dysfunction, hypofibrinogenemia and hemorrhagic diathesis are contraindicated. 10. Patients with severe liver dysfunction, severe hypertension, hypofibrinogenemia and bleeding diseases should not use this drug. 11. The dosage should be used with caution in the elderly and patients with severe atherosclerosis.

Precautions for children: The safety and effectiveness of this product in children have not been reported. Precautions for pregnancy and lactation: Animal experiments show that this product has no damage to the reproductive capacity and fetus of female mice and rats at 1000 times the human dose. There are no reports of carcinogenicity in long-term use. There are no reports of the use of this product in pregnant women with a strict control group. Therefore, pregnant women should not use this product unless it is urgently needed. There are no reports on whether this product can be excreted from breast milk. Therefore, lactating women should use this product with caution. Precautions for the elderly: The safety and effectiveness of this product in elderly patients have not been reported. However, people over 70 years old should use it with caution.

Wuhan Humanwell Pharmaceutical Co., Ltd.

• Founded in:

  1997-06-02

• Address:

  No. 8, Shenghuyuan Road, East Lake New Technology Development Zone, Wuhan, Hubei

• Tax NO.:

  914201003001966747

• Registered Funds:

  260 million yuan

• Website:

  Log in to view

• Email:

  Log in to view